Charles River Laboratories International, Inc. and Atomwise, Inc. recently announced the formation of a strategic alliance that offers clients access to Atomwise’s artificial intelligence (AI)-powered, structure-based, drug design technology, which allows scientists to predict how well a small molecule will bind to a target protein of interest
Ocular Therapeutix, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for DEXTENZA (dexamethasone ophthalmic insert)
On the final day of the largest biotechnology and pharmaceutical partnering week at the Juvenescence Longevity Showcase two leading longevity biotechnology companies, Elevian and Insilico Medicine, announced a research and development partnership to develop oral medications targeting the GDF11 pathway and associated targets
Numerate, Inc., a data-driven drug design company applying artificial intelligence (AI) to transform drug discovery, announced a multi-target research collaboration with Lundbeck Pharmaceutical to identify clinical candidates for the treatment of disorders in the central nervous system, including depression, psychosis, seizure and neurodegenerative disorders
CytoReason, a leader in machine learning for drug discovery and development, announced recently that it has entered into a collaboration agreement with Pfizer Inc. (NYSE:PFE) that will leverage CytoReason’s cell-centered models of the immune system
Horizon Pharma plc and HemoShear Therapeutics, LLC, a privately held biotechnology company, recently announced a collaboration to discover and develop novel therapeutics for gout
Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, recently announced a license agreement with Corvidia Therapeutics Inc
Pharma major Lupin Limited (Lupin) and global biopharmaceutical company AbbVie Inc., recently announced that AbbVie has licensed Lupin’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program
Ayala Pharmaceuticals, Inc., a clinical-stage company developing medicines for cancers that are genetically identified, announced recently that it entered into an option to license agreement with Novartis for its investigational agent AL102 in multiple myeloma
Spirita Oncology, LLC, announced that it has entered into a sublicense agreement with JS Innopharm (Shanghai) Ltd. to initiate global clinical development of E6201, a potent MEK1 inhibitor with excellent brain penetration. In August 2018, Strategia Holdings, LLC, a parent company of Spirita Oncology, LLC, and JS Innopharm initiated a Strategic Partnership Alliance to facilitate global drug development
|
|
|
|
|
|
|
|
|